# LETTER TO THE MJM

# **INTRAOPERATIVE MYOCARDIAL**

## **PROTECTION: WHERE ARE WE GOING IN THE FUTURE?**

#### **Dear MJM:**

One of the limiting factors during cardiac surgery is the amount of ischemia that the heart can be subjected to before the myocardium becomes irreversibly damaged. Over the past half century, advances in intraoperative myocardial protective techniques have dramatically reduced the mortality and morbidity associated with certain invasive procedures such as coronary artery bypass grafting and valve replacement and repair (1). The evolution of intraoperative myocardial protection has traced a fascinating path in recent years and the present discussion provides a brief overview of these advances.

Since its introduction into clinical practice by Bigelow et al. at the University of Toronto over 40 years ago, hypothermia (the cooling of the myocardium) has remained the gold standard for intraoperative myocardial protection. The goal of this technique is to decrease myocardial metabolism during the ischemic period once the aorta is cross-clamped and blood flow to the heart is terminated (2,3).

Cardioplegia, the elective arrest of cardiac activity, is necessary during heart surgery to ensure a quiet surgical field. Recently, cardiac surgeons have used normothermic (37°C) blood cardioplegia as their method of myocardial protection, based on principles developed by Salerno et al. at McGill University and later continued at the University of Toronto (4-6). The aim of these normothermic techniques is to minimize myocardial ischemia bycontinuously supplying oxygen and warm blood to the arrested heart. This allows aerobic resuscitation of injured myocardium. Moreover, normothermic blood cardioplegia avoids many of the adverse effects caused by hypothermia, such as the depletion of high-energy phosphates (7,8) and delays in the recovery of metabolism and function following reperfusion (8,9).

Continuous normothermic blood cardioplegia was initially administered in an antegrade manner by perfusing the coronary arteries and grafts. However, the technique has evolved toward retrograde continuous normothermic blood cardioplegia (5), whereby the cardioplegic agent is perfused via the coronary sinus. This method allows for the rapid perfusion of ischemic or acutely infarcted myocardium, thereby minimizing the period of ischemia. This eliminates the mandatory waiting period required during antegrade delivery when the anastomoses between the graft and the ischemic myocardium are being completed. The retrograde technique eliminates the need for direct ostial cannulation in aortic valve surgery which is required during antegrade delivery. Retrograde cardioplegia is superior to antegrade cardioplegia by providing better cardioplegic delivery in patients with coronary artery stenoses, mild to moderate aortic insufficiency, short left main coronary arteries, or anomalous coronary arteries (10).

Continuous warm blood cardioplegia, whether delivered in an antegrade or retrograde manner, delivers a continuous supply of oxygen and warm blood to the heart. Early clinical results reported by Khan et al. (11) and Panos et al. (12-14) suggest that this technique may be of particular benefit for high-risk patients such as elderly patients (12), patients with diminished left ventricular function (13), and patients with ischemic mitral regurgitation in cardiogenic shock (14). Clinical reviews of cardiac surgery using continuous warm blood cardioplegia in these three patient populations have yielded results that are similar to those of studies using

other myocardial protective techniques. The benefits reported in these patient populations may be attributed to the rapid resuscitation of the injured myocardium and the accelerated return of normal metabolic processes (15,16), both occurring while the heart is maintained in aerobic diastolic arrest. Moreover, the period of ischemia associated with hypothermic myocardial protective techniques is significantly reduced.

Some surgeons have recently begun using alternating administration of antegrade and retrograde cold blood cardioplegia to perfuse the heart in order to take advantage of both techniques (17,18). As mentioned earlier, retrograde perfusion enhances perfusion to the ischemic myocardium distal to coronary artery stenoses. Antegrade perfusion, on the other hand, results in rapid diastolic arrest, and provides enhanced perfusion of the right ventricle (17,19,20). Thus, the use of alternating retrograde and antegrade cardioplegia (21,22). This approach has recently evolved into simultaneous delivery of antegrade/retrograde cardioplegia (23). Recent experimental and clinical studies using simultaneous antegrade/retrograde cardioplegia have shown encouraging results, since the technique combines the advantages of the two routes of administration without untoward effects on the myocardium (23). This method is an important addendum to the current repertoire of myocardial protective techniques available to the cardiac surgeon.

World-wide interest in both continuous warm blood cardioplegia and simultaneous antegrade/retrograde cardioplegia continues to grow. This is evident by the increasing number of articles and conferences devoted to these techniques and it is likely that they will play an integral role in the future of myocardial protection. Moreover, there has been a re-examination of traditional hypothermic techniques and the principles on which they were based. Further investigations are required to assess the metabolic effects of these new techniques. It is almost certain that the area of intraoperative myocardial protection will continue to evolve as we look toward the 21st century.

Shawn J. Khan, B.Sc. Faculty of Medicine McGill University Montreal, QC, Canada H3G 1Y6

Anthony L. Panos, M.D. School of Medicine University of Washington Seattle, WA 98195-6340, USA

Tomas A. Salerno, M.D. Faculty of Medicine University of Toronto Toronto, ON, Canada M5S 1A8

1. Chiu RCJ. Myocardial Protection During Bypass Surgery: Theory and Practice. New York, NY: Praeger, 13-34; 1986.

2. Bigelow WG, Lindsay WK, Greenwood WF. Hypothermia: its possible role in cardiac surgery. Annals of Surgery 132: 849-866; 1950.

3. Shumway NE, Lower R. Hypothermia for extended periods of anoxic arrest. Surgical Forum 10: 563; 1959.

4. Panos AL, Kingsley SJ, Hong AP, Salerno TA, Lichtenstein SV. Continuous warm blood cardioplegia.

Surgery Forum 61: 233-235; 1990.

5. Salerno TA, Houck JP, Barrozo CAM, et al. Retrograde continuous warm blood cardioplegia: a new concept in myocardial protection. Annals of Thoracic Surgery 51: 245-247; 1991.

6. Salerno TA. Continuous blood cardioplegia: option for the future or return to the past? Journal of Molecular and Cellular Cardiology 22 (Suppl. V): S49 (Abstract); 1990.

7. Weisel RD, Mickle DAG, Finkle CD, Tumiati LC, Madonik M, Ivanov J. Delayed myocardial recovery after blood cardioplegia. Annals of Thoracic Surgery 48: 503-507; 1989.

8. Christakis GT, Weisel RD, Mickle DAG, et al. Right ventricular function and metabolism. Circulation 82 (Suppl. IV): IV-332 - IV-340; 1990.

9. Breisblatt WM, Stein KL, Wolfe CJ, et al. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. Journal of the American College of Cardiology 15: 1261-1269; 1990.

10. Menasche P, Piwicna A. Cardioplegia by way of the coronary sinus for valvular and coronary surgery. Journal of the American College of Cardiology 18: 628-636; 1991.

11. Khan SJ, Panos AL, Salerno TA. Continuous normothermic blood cardioplegia in high risk patients. Abstract presented at the McGill University Health Science Exhibition, Montreal, Quebec, March, 1994.

12. Panos AL, Khan SJ, Del Rizzo D, Barrozo CAM, Salerno TA. Continuous normothermic blood cardioplegia in the elderly using normothermic techniques. Cardiology in the Elderly, 1995, In press.

13. Panos AL, Barrozo CAM, Al-Nowaiser O, Ali IS, Khan SJ, Salerno TA. Continuous normothermic blood cardioplegia in patients with severe ventricular dysfunction, 1995, In preparation.

14. Panos AL, Khan SJ, Barrozo CAM, Ali IS, Al-Nowaiser O, Salerno TA. Retrograde continuous normothermic blood cardioplegia in surgery for acute ischemic mitral regurgitation reduces operative mortality. Canadian Journal of Cardiology, 1995, Submitted.

15. Rosenkranz ER, Vinten-Johansen J, Buckberg GD, Okamoto F, Edwards H, Bugyi H. Benefits of normothermic induction of blood cardioplegia in energy-depleted hearts, with maintenance of arrest by multidose cold blood cardioplegic infusions. Journal of Thoracic and Cardiovascular Surgery 84: 667-677; 1982.

16. Buckberg GD. Recent progress in myocardial protection during cardiac operations. Cardiovascular Clinics 17: 291-319; 1987.

17. Partington MT, Acar C, Buckberg GD, et al. Studies of retrograde cardioplegia. II. Advantages of antegrade/retrograde cardioplegia to optimize distribution in jeopardized myocardium. Journal of Thoracic and Cardiovascular Surgery 97: 613-622; 1989.

18. Bhayana JN, Kalmbach T, McLBooth FV, et al. Combined antegrade/retrograde cardioplegia for myocardial protection: a clinical trial. Journal of Thoracic and Cardiovascular Surgery 98: 956-960; 1989.

19. Shiki K, Masuda M, Yonenaga K, Asou T, Tokunaga K. Myocardial distribution of retrograde flow through the coronary sinus of the excised normal canine heart. Annals of Thoracic Surgery 41: 265-271; 1986.

20. Stirling MC, McClanahan TB, Schott RJ, et al. Distribution of cardioplegic solution infused antegradely and retrogradely in normal canine hearts. Journal of Thoracic and Cardiovascular Surgery 106: 1066-1077; 1989.

21. Buckberg GD, Beyersdorf F, Kato NS. Technical considerations and logic of antegrade and retrograde blood cardioplegic delivery. Seminars in Thoracic and Cardiovascular Surgery 5: 123-133; 1993.

22. Aldea GS, Hou D, Fonger JD, Shemin RJ. In homogeneous and complementary delivery of antegrade and retrograde cardioplegia in the absence of coronary artery obstruction. Journal of Thoracic and Cardiovascular Surgery (in press); 1995.

23. Ihnken K, Morita K, Buckberg GD, et al. Simultaneous arterial and coronary sinus perfusion: an experimental/clinical study of a new cardioprotective strategy in high-risk patients. Thoracic and Cardiovascular Surgeon 42: 141-147; 1994.

### BIOGRAPHY

Shawn J. Khan received his B.Sc. degree in physiology from McGill University (Montreal, Quebec) in 1992. He is presently a fourthyear medical student at McGill.

Copyright © 1995 by MJM